During the past decade, University Hospital Tübingen conducted 124 clinical trials. In the 10-year time frame, 124 clinical trials started and 8 clinical trials were completed, i.e. on average, 6.5% percent of trials that started reached the finish line to date. In the past 5 years, 70 clinical trials started and 6 clinical trials were completed. i.e. 8.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Hospital Tübingen" #1 sponsor was "University Hospital Tuebingen" with 80 trials, followed by "University Women's Hospital Tübingen" with 5 trials sponsored, "Celgene" with 4 trials sponsored, "Institut fuer Frauengesundheit" with 3 trials sponsored and "University Hospital Muenster" with 3 trials sponsored. Other sponsors include 68 different institutions and companies that sponsored additional 72 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Hospital Tübingen" #1 collaborator was "University Hospital Tuebingen" with 7 trials as a collaborator, "Arbeitsgemeinschaft fur Internistische Onkologie" with 2 trials as a collaborator, "Boehringer Ingelheim" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator and "Charles University, Czech Republic" with 2 trials as a collaborator. Other collaborators include 239 different institutions and companies that were collaborators in the rest 232 trials.

According to Clinical.Site data, the most researched conditions in "University Hospital Tübingen" are "Rare Diseases" (7 trials), "Genetic Predisposition" (5 trials), "COVID-19" (4 trials), "Malignant Melanoma" (4 trials) and "Septic Shock" (4 trials). Many other conditions were trialed in "University Hospital Tübingen" in a lesser frequency.

Most popular intervention types in "University Hospital Tübingen" are "Drug" (65 trials), "Device" (24 trials), "Other" (19 trials), "Procedure" (15 trials) and "Biological" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Lenalidomide" (2 trials), "NGS Diagnostic" (2 trials), "Next Generation Sequencing (NGS)" (2 trials) and "anodal transcranial direct current stimulation" (2 trials). Other intervention names were less common.

The vast majority of trials in "University Hospital Tübingen" are 151 trials for "All" genders, 12 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "University Hospital Tübingen". 3 are not yet recruiting, 53 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 56 completed trials in University Hospital Tübingen, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in University Hospital Tübingen, 12 "Phase 1" clinical trials were conducted, 40 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 48 trials that are defined as “Not Applicable".